Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations

Berrocal, A.; Cabañas, Luis; Espinosa, Enrique; Fernández-de-Misa, Ricardo; Martín‐Algarra, Salvador; Martínez-Cedres, José Carlos; Ríos‐Buceta, L.; Rodríguez‐Peralto, José Luis

doi:10.1007/s12325-014-0148-2

Cited by 38 publications

(26 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 The worldwide incidence of melanoma among light-skinned populations has increased faster than any other malignancy in recent decades. 3 In Europe, the estimated age-adjusted incidence and mortality rates of melanoma in 2018 were 15.8 and 3.2 per 100 000 in men and 14.6 and 1.9 per 100 000 in women, respectively. 2 In Europe, melanoma epidemiology shows a clear north-south gradient.…”

Section: Introductionmentioning

confidence: 99%

Trends in mortality from cutaneous malignant melanoma in Spain (1982–2016): sex‐specific age‐cohort‐period effects

Gutiérrez‐González

López‐Abente

Aragonés

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Mortality from malignant cutaneous melanoma increased alarmingly during the second half of the 20th century in Spain and other European countries. Objective The aim was to analyse sex‐ and age‐specific trends in melanoma mortality in Spain in the period 1982–2016. Methods European age‐standardized melanoma mortality rates during the period 1982–2016 were calculated from mortality figures provided by the National Statistics Institute. Joinpoint regressions were used to identify significant points of change in trends and to compute average annual per cent change (AAPC). Age‐cohort‐period models were fitted to explore the effect of these variables on mortality. Results During the period 1982–2016, age‐standardized melanoma mortality rates increased in Spain from 0.90 to 1.80 deaths per 100 000 people in men and from 0.64 to 1.11 per 100 000 in women, rising noticeably from 1982 to 1995 in both sexes and in all age groups. From the mid‐90s different trends were observed depending on sex and age: there was a decrease in mortality in the population younger than 45 years (AAPC ‐2 in both sexes) and aged 45–64 years (AAPC ‐1 among men and ‐0.2 among women), but in the group over 64 years rates continued to increase (AAPC 1.7 and 0.2, respectively, for men and women). The mortality sex ratio decreased in the younger population but increased in older individuals. A cohort effect was observed with lower mortality in the cohorts born after 1943 in men and 1956 in women. There was also a period effect with decreased mortality rates at the beginning of the 1990s. Conclusions Melanoma mortality rates in Spain increased during the last decades of the 20th century; however, later they stabilized in women and began to decrease in younger cohorts and middle‐aged men. Promotion of primary and secondary prevention measures should continue, with particular emphasis on males over 65 years.

show abstract

Section: Introductionmentioning

confidence: 99%

Trends in mortality from cutaneous malignant melanoma in Spain (1982–2016): sex‐specific age‐cohort‐period effects

Gutiérrez‐González

López‐Abente

Aragonés

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Melanoma is the most aggressive form of skin cancer due to its capacity to form metastases 13. Aside from that, various experimental and clinical data indicate that melanoma cells are susceptible to NK cell and CTL-mediated cytotoxicity 14.…”

Section: Introductionmentioning

confidence: 99%

Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Although nowadays attention mostly focuses on advanced MM, localized disease accounts for roughly 93% of cases and thickness of MM is lower than 1 mm in more than half of primary tumours [16]. Since those patients are mainly followed by dermatologists both in multidisciplinary MM units [20] and general dermatology clinics, improved and reliable tools to detect patients who are at risk of progression are welcomed. The results herein support a previous report [21] on an 8% shift of cases from a T1a towards a T1b stage as the 8th edition is implemented.…”

Section: Discussionmentioning

confidence: 99%

Disease-Free Survival for Patients with Thin Melanomas according to the American Joint Committee on Cancer 8th Edition

et al. 2019

View full text Add to dashboard Cite

Background: The recently implemented AJCC 8th edition TNM staging system for malignant melanoma (MM) changed the definition for T1a and T1b tumours. Objectives: To analyse differences in disease-free survival (DFS) among patients with thin MM staged according to both AJCC 7th and 8th editions. Methods: An observational study including 285 patients with cutaneous thin MM (thickness ≤1 mm). Cases were staged as T1a and T1b using both 7th and 8th editions. Neither regional nor visceral diseases were present at diagnosis. DFS curves were generated according to the Kaplan-Meier method. Results: An 8% shift of patients from a T1a towards a T1b stage group was observed after applying the AJCC 8th edition. According to this 8th edition, DFS for T1a patients was significantly longer than for T1b patients (log-rank test; p = 0.005); 5-year DFS for T1a and T1b was 100 and 95%, respectively (Wilcoxon test; p = 0.002). According to the AJCC 7th edition, DFS did not significantly differ for T1a and T1b patients; 5-year DFS for T1a and T1b was 99 and 97%, respectively (p > 0.05). Conclusions: The AJCC 8th edition seems to be a better tool for staging thin melanomas.

show abstract

Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations

Cited by 38 publications

References 103 publications

Trends in mortality from cutaneous malignant melanoma in Spain (1982–2016): sex‐specific age‐cohort‐period effects

Trends in mortality from cutaneous malignant melanoma in Spain (1982–2016): sex‐specific age‐cohort‐period effects

Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma

Disease-Free Survival for Patients with Thin Melanomas according to the American Joint Committee on Cancer 8th Edition

Contact Info

Product

Resources

About